PCSK9 and atherosclerosis: As shown in Table 2, the main research areas include cardiac cardiovascular systems (422, 39.37%), pharmacology pharmacy (226, 21.08%), and peripheral vascular disease (132, 12.31%), etc. For journal ranking, most papers related to PCSK9 inhibitors were published in the following journals: Journal of Clinical Lipidology (66, 6.16%), Atherosclerosis (45, 4.2%), Journal of the American College of Cardiology (31, 2.89%), Circulation (25, 2.33%), and Journal of the American Heart Association (25, 2.33%).